<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466060</url>
  </required_header>
  <id_info>
    <org_study_id>CR-6012</org_study_id>
    <nct_id>NCT03466060</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of 3 Contact Lens Materials With 3 Solution Types</brief_title>
  <official_title>Clinical Evaluation of 3 Contact Lens Materials With 3 Solution Types</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site, randomized, double-masked, contralateral, 2 treatment x 2 period
      crossover, dispensing, five-visit study to gain clinical insights of the study lenses and
      solutions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comfort</measure>
    <time_frame>Up to 2 hours post lens insertion</time_frame>
    <description>Subjective assessment of initial comfort will be conducted using Visual Analogue Scale (VAS) of comfort. VAS of comfort consists of a vertical line which represents continuous scale from 0 (extremely uncomfortable) to 100 (extremely comfortable). VAS comfort will be administered at 1-min, 5-min, 45-min and 2-hours post-fit.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Visual Acuity, Slit Lamp Biomicroscopy (Corneal Staining Assessment)</condition>
  <arm_group>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etafilcon A will be used to evaluate 3 lens solutions; Opti-Free, RevitaLens, and Clear Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>senofilcon A will be used to evaluate 3 lens solutions; Opti-Free, RevitaLens, and Clear Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>senofilcon C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>senofilcon C will be used to evaluate 3 lens solutions; Opti-Free, RevitaLens, and Clear Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Opti-Free : RevitaLens / Clear Care : RevitaLens</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Left eye : right eye / left eye : right eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Opti-Free : RevitaLens / RevitaLens : Clear Care</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Left eye : right eye / right eye : left eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clear Care : RevitaLens/ Opti-Free : RevitaLens</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Left eye : right eye / left eye : right eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clear Care : RevitaLens / RevitaLens : Opti-Free</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Left eye : right eye / right eye : left eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RevitaLens : Clear Care/ Opti-Free : RevitaLens</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Right eye : left eye / left eye : right eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RevitaLens : Clear Care / RevitaLens : Opti-Free</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Right eye : left eye / right eye : left eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RevitaLens : Opti-Free / Clear Care : RevitaLens</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Right eye : left eye / left eye : right eye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RevitaLens : Opit-Free / RevitaLens : Clear Care</intervention_name>
    <description>Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.</description>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_label>senofilcon A</arm_group_label>
    <arm_group_label>senofilcon C</arm_group_label>
    <other_name>Right eye : left eye / right eye : left eye</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Potential subjects must satisfy all of the following criteria to be enrolled in the
             study:

               1. Subjects must be 18-69 years of age (inclusive).

               2. Subjects must be habitual disposable hydrogel or silicone hydrogel (1-day,
                  2-week, or monthly replacement schedule) soft lens wearer in both eyes. Habitual
                  is defined as at least one (1) month of contact lens wear where the lenses are
                  worn for a minimum of six (6) hours per day and a minimum of five (5) days per
                  week.

               3. Subjects must have best corrected visual acuity of 20/25 (Snellen or equivalent)
                  or better in each eye.

               4. The subject's refractive sphere (vertexed) must be between -1.00 and -6.00 D in
                  each eye.

               5. The subject's refractive cylinder must be less than or equal to -1.00 D in each
                  eye.

               6. The subject must have normal eyes (i.e., no ocular medications or infections of
                  any type).

               7. Subjects must possess a functional/usable pair of spectacles and bring them to
                  the visit (only if applicable - to the investigators discretion).

               8. Subjects must read, understand, and sign the Statement of Informed Consent.

               9. Subjects must appear able and willing to adhere to the instructions set forth in
                  this clinical protocol.

                  Exclusion Criteria:

          -  Potential subjects who meet any of the following criteria will be excluded from
             participating in the study:

               1. Currently pregnant or breast-feeding.

               2. Diabetes

               3. Any ocular or systemic allergies or disease which may interfere with contact lens
                  wear (at the discretion of the investigator).

               4. Any systemic disease, autoimmune disease, or use of medication which may
                  interfere with contact lens wear (at the discretion of the investigator).

               5. Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious
                  immunosuppressive disease (eg, HIV), by self-report.

               6. Current habitual use of Restasis, Xiidra, ocular steroids, or any medication (RX
                  or OTC) that may interfere with contact lens wear (at the discretion of the
                  investigator).

               7. Grade 2 or greater corneal staining or conjunctival injection on the FDA scale.

               8. Clinically significant (Grade 3 or greater on the FDA scale) corneal edema,
                  corneal vascularization, or any other abnormalities of the cornea (excluding
                  corneal staining) which would contraindicate contact lens wear.

               9. Clinically significant (Grade 3 or greater on the FDA scale) tarsal abnormalities
                  which might interfere with contact lens wear.

              10. Any active ocular abnormalities/conditions that may interfere with contact lens
                  wear (at the discretion of the investigator).

              11. Any corneal distortion due to previous rigid gas permeable lens wear, surgery or
                  pathology.

              12. History of any ocular or corneal surgery (eg, RK, PRK, LASIK).

              13. Habitual contact lens wear modality as extended wear.

              14. Participation in any pharmaceutical or medical device related clinical trial
                  within 7 days prior to study enrollment.

              15. History of binocular vision abnormality or strabismus.

              16. Habitual wearers of rigid gas permeable lens within the past 3 months.

              17. Employees of investigational clinic (investigator, coordinator, and technician
                  etc.) or family members of employees of the investigational clinic by self-report
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meredith Bishop, OD, MS, FAAO</last_name>
    <phone>1-800-843-2020</phone>
    <email>mbishop4@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern California College of Optometry</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Berkeley School of Optometry</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Houston College of Optometry</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

